Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 4/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449985 | 0.95 | CCKBR (0.32) | CALCRLCCR1 | |
| SCHEMBL3449253 | 0.94 | CCKBR (0.31) | CCR1 | |
| SCHEMBL6015073 | 0.90 | CCR1 (0.40) | CCR1TP53 | |
| SCHEMBL6015003 | 0.88 | CCKBR (0.40) | CCR1 | |
| SCHEMBL6015112 | 0.88 | CCR1 (0.38) | CCR1TP53 | |
| SCHEMBL6015148 | 0.87 | UBE2N (0.41) | CCR1TSHRKMT2A | |
| SCHEMBL3447639 | 0.86 | MAPK1 (0.32) | CALCRLCCR1TP53KMT2A | |
| SCHEMBL6015029 | 0.86 | CCR1 (0.40) | CALCRLCCR1KMT2ACACNA1B | |
| SCHEMBL6014965 | 0.85 | CCR1 (0.39) | CCR1TP53 | |
| SCHEMBL3449306 | 0.84 | TSHR (0.31) | CCR1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820673-B2 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | F2, URB2, F12 | CALCRL 2629/4885CCR1 2570/4885TP53 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.